Patent ID: 7807686

Claim:
A 2-(4-oxo-4H-quinazolin-3-yl)acetamide compound of formula I, wherein R 1 is C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-2 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl or benzyl, said C 1-6 alkyl, C 3-6 cycloalkyl and C 3-6 cycloalkylC 1-2 alkyl being optionally substituted with one or more halogens; R 2 is a group selected from C 6-10 aryl optionally substituted with one to three substituents selected from halogen, hydroxy, cyano, COOR 13 , NR 14 R 15 , pyrrole, C 1-6 alkyl, C 3 -6 cycloalkyl, C 1-6 alkyloxy and C 3-6 cycloalkyloxy, said C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxy and C 3-6 cycloalkyloxy being optionally substituted with one or more halogens, wherein R 13 and R 14 are independently H or C 1-6 alkyl and R 15 is H, C 1-6 alkyl or C 1-6 acyl, and C 4-7 cycloalkyl or R 2 is a 5-10 membered heteroaryl ring system comprising a heteroatom selected from N, O and S optionally substituted with a substituent selected from methyl, C 1-6 alkyloxy and halogen; R 3 is one or two substituents selected from H, C 1-6 alkyl, C 1-6 alkyloxy and halogen, said C 1-6 alkyl and C 1-6 alkyloxy being optionally substituted with one or more halogens; R 4 is a group located at the 6- or 7-position of the quinazoline ring and is selected from each R 5 is independently H or C 1-6 alkyl or one of R 5 when joined together with one of R 6 or R 7 forms a 5-6 membered heterocyclic ring; R 6 and R 7 are independently H, C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-2 alkyl, C 6-10 aryl or C 6-10 arylC 1-2 alkyl; or R 6 and R 7 together with the nitrogen to which they are bound form a 4 to 8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR 10 , said heterocyclic ring being optionally substituted with one or two substituents selected from halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkyloxy, cyano and COOR 11 and said heterocyclic ring being optionally fused at two adjacent carbon atoms to a phenyl ring; or one of R 6 and R 7 when joined together with one of R 5 forms a 5-6 membered heterocyclic ring; R 8 is one or two substituents selected from H, C 1-6 alkyl, C 1-6 alkyloxy and halogen or one of R 8 when joined together with R 9 forms a 5-6 membered ring; R 9 is H or C 1-6 alkyl or R 9 when joined together with one of R 8 forms a 5-6 membered ring; R 10 is H, C 1-6 alkyl or C 1-6 acyl; R 11 is H or C 1-6 alkyl; m is 2-4; n is 1-2; X is CH 2 , O, S, SO 2 or NR 12 ; R 12 is H, C 1-6 alkyl, C 1-6 acyl or a C 6-10 aryl C 1-2 alkyl group, said C 6-10 aryl C 1-2 alkyl group being optionally substituted with methyl or methoxy; Y is CH 2 , (CH 2 ) 2 or (CH 2 ) 3 ; Q, T, V and W are C or N with the proviso that one of Q, T, V and W is N and the others are C; Q′, T′ and V′ are selected from C, O, N and S with the proviso that one of Q′, T′ and V′ is O, N, or S and the others are C; or a pharmaceutically acceptable salt thereof.